Results: A total of 316 patients were randomised to XP (n = 160) or FP (n = 156). In the per-protocol population, median PFS for XP (n = 139) versus FP (n = 137) was 5.6 versus 5.0 months. The primary end point was met with an unadjusted hazard ratio (HR) of 0.81 [95% confidence interval (CI) 0.63-1.04, P < 0.001 versus noninferiority margin of 1.25]. Median overall survival was 10.5 versus 9.3 months for XP versus FP (unadjusted HR = 0.85, 95% CI 0.64-1.13, P = 0.008 versus noninferiority margin of 1.25). The most common treatment-related grade 3/4 adverse events in XP versus FP patients were as follows: neutropenia (16% versus 19%), vomiting (7% versus 8%), and stomatitis (2% versus 6%).
introduction
Although advanced gastric cancer (AGC) is sensitive to numerous agents, response rates with monotherapy are generally low-in the range of 10%-30% [1] . It is now well recognised that combination chemotherapy regimens improve patient outcomes, but there is no accepted global standard regimen. 5-Fluorouracil (5-FU) given as a continuous infusion in combination with cisplatin (FP) has consistently demonstrated superiority in terms of response rate and time to disease progression compared with 5-FU monotherapy and other combination regimens, although it has not shown a significant survival advantage [2] [3] [4] . As a result of these findings, FP was subsequently adopted as a standard reference regimen in Korea and many other countries.
In Europe, triple combination regimens have been widely tested, and epirubicin/cisplatin-5-FU (ECF) is accepted as a standard regimen in the UK and parts of Europe. Triple therapy recently received further support from a meta-analysis which showed a significant overall survival (OS) benefit with triple drug regimens containing 5-FU, an anthracycline and cisplatin compared with FP or 5-FU-anthracycline doublets [5] ; however, the interpretation of this analysis, which was based on only three randomised trials, has been criticised [6, 7] . Study V325 also reported a significant improvement in survival when docetaxel was added to FP, although the advantage in clinical terms was small and the regimen was associated with considerable haematological toxicity [8] . Therefore, FP remains a widely accepted standard treatment option for patients with AGC.
Capecitabine (XelodaÒ, F. Hoffmann-La Roche) is an oral fluoropyrimidine designed to mimic a continuous infusion of 5-FU. Capecitabine has shown good response rates in patients with AGC when given as monotherapy (19%-34%) [9] [10] [11] or in combination with cisplatin (55%) in phase II studies [12] . Replacing 5-FU with capecitabine in combination with cisplatin avoids the need for continuous infusions and combines two agents that have few overlapping toxic effects [12, 13] . REAL-2 recently demonstrated that capecitabine can replace 5-FU when used as part of a triple combination regimen in patients with AGC [14] . The aim of this phase III study was to compare the efficacy and safety of capecitabine/cisplatin (XP) with that of 5-FU/cisplatin (FP) in the first-line treatment of AGC.
patients and methods

study design
This was a randomised, open-label, international, multicentre, phase III study of XP versus FP conducted in Asia, Europe, and Latin America. Patients who met the inclusion/exclusion criteria were randomised to XP or FP in a 1 : 1 ratio. Roche produced the randomisation list, which was stratified by region (Korea, China, Russia, and Central/South America). A random permuted block design was used within each of the four regions with a block size of four. The primary study objective was to confirm noninferiority of XP compared with FP for progression-free survival (PFS) in patients with AGC. The study was open label because of the different routes of administration of the fluoropyrimidine components of the XP and FP regimens. The study was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. Written informed consent was obtained from all patients participating in the study. The protocol was approved by the institutional review board at each centre.
patients
Inclusion criteria for the study were as follows: age 18-75 years; Karnofsky performance status of seventy or more; histologically confirmed measurable AGC; no previous chemotherapy other than neo-adjuvant or adjuvant regimens; no radiotherapy to target lesions; and adequate renal, hepatic, and cardiac function. Adequate renal function was defined as an estimated creatinine clearance ‡60 ml/min using the Cockcroft and Gault formula. Pregnant or breast-feeding women were excluded. Other key exclusion criteria were as follows: clinically significant cardiovascular disease, evidence of central nervous system metastases, and major surgery or trauma in the previous 4 weeks.
study treatment
Patients were randomised 1 : 1 to receive cisplatin 80 mg/m 2 as a 2-h i.v.
infusion on day 1 with hyperhydration plus either oral capecitabine (XP) 1000 mg/m 2 twice daily on days 1-14 every 3 weeks or 5-FU (FP) 800 mg/ m 2 /day by continuous infusion on days 1-5 every 3 weeks. The dose intensity of this 3-weekly regimen is equal to that of standard 4-weekly regimens. Patients were treated until disease progression or lack of clinical benefit, withdrawal of consent, justifiable withdrawal at the investigator's discretion, or toxicity. All patients were followed for survival to end of study regardless of discontinuation of treatment.
study assessments and end points
The primary study end point was PFS, measured as time from randomisation to the date of first documented disease progression or death, whichever occurred first. Secondary end points were as follows: OS (defined as time from randomisation to the date of death or the last date the patient was known to be alive), objective response rate (ORR), duration of response, time to response, and safety. Efficacy was evaluated by tumour assessments, which were confirmed at least 4 weeks after the first recorded response. Baseline tumour assessments were made within 21 days before treatment start by a suitable reproducible technique (computed tomography scan, magnetic resonance imaging, or X-rays). Tumour assessments were performed every two cycles according to the Response Evaluation Criteria in Solid Tumours [15] , and took into account the responses in target and non-target lesions and the appearance of new lesions compared with the previous assessment. A complete response was defined as: disappearance of all target and nontarget lesions; normalisation of tumour marker levels; and no new lesions. A partial response was defined as: at least 30% decrease in the sum of the longest diameter of target lesions versus baseline; persistence of one or more non-target lesions without progression and/or maintenance of tumour marker levels above normal limits; and no new lesions. An independent review committee (IRC) reviewed patients' radiological images and assessed tumour responses without knowledge of treatment assignment.
Safety was evaluated by the occurrence of adverse events, which were monitored every cycle and classified according to the National Cancer Institute Common Toxicity Criteria (version 2.0), laboratory values, and vital signs.
statistics
The intent-to-treat (ITT) population included all randomised patients. Patients were excluded from the per-protocol (PP) population if they received <6 weeks of treatment for reasons other than progressive disease or death or <50% of the anticipated treatment during the first 6 weeks of the trial, if there were major inclusion/exclusion criteria violations or if there was inadequate information on tumour burden. The safety population included all patients who received at least one dose of study medication and who had at least one postbaseline safety assessment.
The primary analysis of PFS was of the noninferiority of XP to FP, as measured by the hazard ratio HR XP/FP with a noninferiority margin of 1.40; this was based on results from two clinical trials [2, 3] . H 0 was rejected if the upper limit of the 95% confidence interval (CI) was less than the noninferiority margin. If the null hypothesis versus 1.40 was rejected then a prespecified sequence of hierarchical tests was conducted. The second test was against the noninferiority margin of 1.25; the final test was the superiority of XP compared with FP. Here, all tests of noninferiority are reported against the noninferiority margin of 1.25. The primary analysis (Cox regression stratified by geographic region and adjusted for prespecified prognostic factors) was conducted in the PP population as recommended for noninferiority trials. A secondary analysis was an unadjusted Cox regression stratified by geographic region. The equality of the treatment effect, as measured by HR XP/FP , across subgroups of prespecified prognostic factors was tested with Cox regression. Survival functions were plotted using the Kaplan-Meier method. The ORRs of XP and FP were compared with the Cochran Mantel Haenszel test stratified by geographic region.
The sample size was set through a computer simulation. For PFS, if the efficacy of XP and FP was assumed to be identical and if the noninferiority margin was set to 1.40, then a sample size of 150 patients in each treatment group and 220 events in total would provide a power of 80% to reject the null hypothesis. The noninferiority margins of 1.40 and 1.25, respectively, provide retentions of effect of 57% and 72% [16] . (Table 1) . Forty patients were excluded from the PP population due to inadequate tumour burden information at baseline (n = 2); insufficient/inadequate follow-up assessment of lesions found at baseline, resulting in inability to determine PFS as well as response (n = 32); violated inclusion/exclusion criteria (n = 11); and received less than two cycles of treatment (n = 16) (note: some patients are counted more than once). Therefore, the PP population included 276 patients (XP, n = 139; FP, n = 137). The safety population comprised 311 patients (XP, n = 156; FP, n = 155) ( Figure 1 ). (Figure 2) . The results for the adjusted analysis were consistent with those of the unadjusted analysis.
The results for PFS in the ITT population were similar to those in the PP population. The median PFS for XP was 5.6 months (95% CI 4.8-6.9) versus 5.0 months for FP (95% CI 3.9-5.7). The unadjusted HR was 0.80 (95% CI 0.63-1.03) and XP was significantly noninferior compared with FP (P < 0.001 versus the noninferiority margin of 1.25). There was a trend towards superior PFS with XP compared with FP (P = 0.0801).
This outcome was supported by the IRC blind assessment of PFS. In the PP population, XP was again significantly noninferior to FP (HR = 0.90, 95% CI 0.69-1.18, P = 0.0169 versus noninferiority margin of 1.25). In both treatment arms, median PFS was 1 month longer than that based on investigators' assessments; median PFS for XP was 6.6 months (95% CI 5.4-8.4) versus 6.1 months for FP (95% CI 5.0-7.1).
For OS in the PP population, XP was highly significantly noninferior compared with FP (unadjusted HR = 0.85, 95% CI 0.64-1.13, P = 0.008 versus noninferiority margin of 1.25). This indicates an observed 15% reduction in the hazard of death with XP compared with FP, although this difference was not statistically significant (P = 0.2650 for test of superiority). Median OS was 10.5 months (95% CI 9.3-11.2) for XP compared with 9.3 months for FP (95% CI 7.4-10.6) ( Figure  3 ). Similar findings were reported in the ITT population (unadjusted HR = 0.85, 95% CI 0.65-1.11, P = 0.005 versus noninferiority margin of 1.25) with a median OS of 10.4 months (95% CI 9.1-11.0) for XP compared with 8.9 months for FP (95% CI 7.3-10.2).
For PFS and OS in the PP population, Cox regression showed there were no significant differences (P > 0.16) between the HRs of XP versus FP for the subgroups of prespecified prognostic factors, and the 95% CIs overlapped substantially (Figure 4) . The similarity of the estimated HRs across the prospectively defined subgroups supports the robustness of the primary analysis. Most of the estimated HRs were <1.0, thus favouring XP over FP, and the 95% CIs contained 1.0, which is to be expected given the small sample sizes of the subgroups.
In the PP population, the ORR and partial response rate were both significantly superior for XP compared with FP original article Annals of Oncology (P = 0.020 and P = 0.013, respectively). The number of complete responses was similar in both treatment arms (2% with XP and 3% with FP). A summary of other secondary end points is given in Table 2 .
safety Most patients (96%) reported at least one adverse event. Both XP and FP were well tolerated and were similar in terms of their safety profiles and percentage of patients with treatment-related adverse events (Table 3 ). The most common treatment-related adverse events generally occurred at similar rates in both treatment arms. However, hand-foot syndrome (HFS) was more frequent with XP than with FP (34 of 156, 22% versus 6 of 155, 4%), but led to treatment discontinuation in only one patient (<1%) in the XP arm, whereas vomiting (91 of 155, 59% versus 76 of 156, 49%) and stomatitis (41 of 155, 26% versus 18 of 156, 12%) were more common in the FP arm. XP and FP were also similar in terms of the percentage of patients experiencing haematological adverse events ( Table 3 ), except that anaemia was more common with XP (27 of 156, 17% versus 12 of 155, 8% with FP). XP and FP were similar in terms of the percentage of patients (50%) experiencing grade 3/4 treatment-related adverse events. Grade 4 adverse events occurred in 13% (20 of 156) of patients in the XP arm and 10% (16 of 155) of patients in the FP arm. The most common nonhaematological grade 3/4 adverse events were vomiting, stomatitis, HFS, and diarrhoea, each of which occurred in 3%-10% of patients in both treatment arms. Overall, the incidence of grade 3/4 haematological adverse events was comparable and low in both Adverse events which led to treatment modifications (defined as interruptions, delays, or dose reductions) occurred in 62% of patients in the XP arm and 48% of patients in the FP arm. In both treatment arms, the most frequent adverse event requiring treatment modification was neutropenia (37 patients in each; 24%). Treatment modification in the XP arm compared with the FP arm was more frequent for anaemia (6% versus 1%), vomiting (8% versus 1%), nausea (6% versus <1%), diarrhoea (7% versus 2%), and HFS (8% versus 0%).
The percentage of patients withdrawn for safety (adverse event or death) and nonsafety (insufficient therapeutic response, patient refusal, lost to follow-up, or other) reasons was similar in each treatment arm. Adverse events leading to treatment discontinuation were reported in 28 patients (18%) in each treatment arm. Gastrointestinal [11 of 156 (7%) and 6 of 155 (4%) of patients in the XP and FP arms, respectively] and haematological adverse events [6 of 156 (4%) and 7 of 155 (5%), respectively] were the most common toxic effects leading to treatment discontinuation in both arms.
Death within 60 days after the start of treatment occurred in 8 of 156 (5%) patients in the XP arm and 5 of 155 (3%) patients in the FP arm. One death (<1%) in the XP arm and two deaths (1%) in the FP arm were considered treatment related by the study investigators. The overall mortality rate during treatment and within 28 days of the last dose was 9% for XP and 6% for FP. Of these, five deaths in the XP arm and three deaths in the FP arm were due to causes other than gastric cancer/progressive disease.
discussion
As measured by the primary end point of PFS, XP was shown to be significantly noninferior to FP versus the noninferiority margin of 1.25 in both the PP (P < 0.001) and ITT (P < 0.001) populations. The median PFS for XP was 5.6 versus 5.0 months for FP in both analyses. This outcome was also confirmed by the IRC assessment. Subgroup analyses of PFS in the PP population also favoured XP over FP, demonstrating the consistency and robustness of the results. In addition, XP was significantly noninferior to FP in terms of OS (P = 0.008 versus the noninferiority margin of 1.25 in the PP population). The ORR with FP (32%) in our study is similar to that reported in more recent phase III trials comparing FP with other 5-FU-based regimens in the treatment of AGC [3, 4] . Thus, the ORR of 46% for XP compares favourably with that obtained for FP in both this and other studies and confirms the consistent advantage of XP in this trial.
XP was as well tolerated as FP; both combinations had a similar safety profile and there were no unexpected toxic effects. Characteristic of fluoropyrimidine-based therapy, gastrointestinal adverse events were among the most frequent toxic effects in both treatment arms. Vomiting and stomatitis were more frequent in the FP arm, while HFS and anaemia were more frequent in the XP arm. Both treatment arms were similar in terms of the percentage of patients discontinuing due to adverse events, 60-day all-cause mortality, and treatmentrelated mortality. The tolerability profile of the 3-weekly FP regimen used in the present study, which has a dose intensity equal to that of the 4-weekly FP regimen used in other phase III studies [8] , is notable. The incidence of grade 3/4 neutropenia with 3-weekly FP was 19% versus 57% with the 4-weekly regimen, and the incidence of complicated/febrile neutropenia was <1% versus 12% with the 4-weekly regimen [8] .
The current findings add to the considerable volume of phase II data documenting the efficacy of capecitabine in the treatment of AGC (for review see Lee and Kang [17] ). They also provide further support for replacing 5-FU with capecitabine in the treatment of AGC. In the pivotal REAL-2 trial in oesophagogastric cancer, pooled capecitabine-based triplet regimens (epirubicin-cisplatin-capecitabine + epirubicinoxaliplatin-capecitabine (EOX); n = 480) showed significant noninferiority to the pooled 5-FU-based triplets (ECF + epirubicin-oxaliplatin-5-FU; n = 484) in terms of median OS (10.9 versus 9.6 months; HR 0.86, 95% CI 0.80-0.99; primary end point), with the upper limit of the 95% CI for the HR well below the predefined value of 1.23 [14] . In addition, EOX was statistically superior to ECF in terms of OS. The safety of capecitabine-based regimens in this trial was also similar to those based on continuous infusions of 5-FU [14] . Also of interest is the recent SPIRITS trial, which reported an improved outcome in terms of OS with oral S-1-cisplatin compared with S-1 alone in the first-line treatment of AGC [18] . The SPIRITS trial again reinforces the validity of using an oral fluoropyrimidine instead of infusional 5-FU in this patient group.
FP has well-established efficacy in Europe, North America, Korea, and Japan [2] [3] [4] 8] . It is a recognised standard reference regimen in several countries and was therefore selected as the control regimen for the present study. Although the further addition of an anthracycline is favoured in the UK and parts of Europe (i.e. ECF), the benefits of this approach versus FP have yet to be demonstrated prospectively. Docetaxel-cisplatin-5-FU, which has shown survival benefits compared with FP in a prospective trial, is not widely accepted because the small efficacy gain is coupled with substantial toxicity [8] . Therefore, even allowing for data that have emerged since the protocol of the current study was written, we suggest that FP remains a valid reference regimen. This is further supported by its selection as the control regimen in several ongoing clinical trials (e.g. FLAGS).
Study ML17032 was conducted in 12 different countries spanning three continents, which increases the generalisability of its findings to the global community. In common with other recent major studies [8, 14] , the patient population in the present study was relatively young (median age 56 years) and had a good average performance status. However, the subgroup analysis (Figure 4) suggests that the findings can be extended to patients with a poorer prognosis.
In conclusion, the current study indicates that XP is an effective and well-tolerated therapy for the first-line treatment of AGC. Capecitabine has the advantage of avoiding the inconvenience and complications associated with infusional i.v. 5-FU and offers the potential for a simplified dosing schedule. The available evidence suggests that capecitabine can replace infused 5-FU for the treatment of AGC and XP should be a new standard treatment option for AGC.
